Zufei Li1, Shuo Ding2, Qi Zhong2, Guojun Li3, Yang Zhang2, Xiaohong ChenZhigang Huang2. 1. Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Key Laboratory of Otolaryngology Head and Neck Surgery (Capital Medical University), Ministry of Education Beijing 100730, China ; Department of Otolaryngology Head and Neck Surgery, Aerospace Center Hospital Beijing 100039, China. 2. Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Key Laboratory of Otolaryngology Head and Neck Surgery (Capital Medical University), Ministry of Education Beijing 100730, China. 3. Department of Head and Neck Surgery and Epidemiology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Abstract
BACKGROUND: To evaluate the association of MMP11 and P14(ARF) expression in laryngeal squamous cell carcinoma (LSCC) with clinical pathological characteristics and survival. METHODS: The mRNA and protein levels for both genes were determined in 65 LSCC patients. A log-rank test and Cox models were used to compare survival among different groups. RESULTS: The mRNA expressions of MMP11 and P14(ARF) were significantly different between LSCC and their corresponding adjacent tissues (All P < 0.001). The expressions of MMP11 and P14(ARF) were correlated with several clinical characteristics (All P < 0.05). Patients with low MMP11 and high P14(ARF) expression had significantly better survival compared with those with high MMP11 and low P14(ARF) expression, respectively (All P < 0.05). The patients with surgery only had significantly better survival than those with chemoradiotherapy (log rank: P = 0.016), particularly in patients with low MMP11 and high P14(ARF) expression (log rank: P = 0.006). Furthermore, multivariable analysis showed that patients with low MMP11 and high P14(ARF) expression alone had a significantly reduced risk of death compared with those with high MMP11 and low P14(ARF) expression. The reduced risk for overall death was pronounced for patients with low and high expression of both genes (HR, 0.2; 95% CI, 0.1-0.5) compared with any other co-expression status of both genes, particularly for patients with surgery only (HR, 0.1; 95% CI, 0.0-0.9). CONCLUSION: These results suggest that altered expression of MMP11 and P14(ARF) in tumors may individually, or in combination, predict poor prognosis of LSCC, particularly for patients with surgery only.
BACKGROUND: To evaluate the association of MMP11 and P14(ARF) expression in laryngeal squamous cell carcinoma (LSCC) with clinical pathological characteristics and survival. METHODS: The mRNA and protein levels for both genes were determined in 65 LSCC patients. A log-rank test and Cox models were used to compare survival among different groups. RESULTS: The mRNA expressions of MMP11 and P14(ARF) were significantly different between LSCC and their corresponding adjacent tissues (All P < 0.001). The expressions of MMP11 and P14(ARF) were correlated with several clinical characteristics (All P < 0.05). Patients with low MMP11 and high P14(ARF) expression had significantly better survival compared with those with high MMP11 and low P14(ARF) expression, respectively (All P < 0.05). The patients with surgery only had significantly better survival than those with chemoradiotherapy (log rank: P = 0.016), particularly in patients with low MMP11 and high P14(ARF) expression (log rank: P = 0.006). Furthermore, multivariable analysis showed that patients with low MMP11 and high P14(ARF) expression alone had a significantly reduced risk of death compared with those with high MMP11 and low P14(ARF) expression. The reduced risk for overall death was pronounced for patients with low and high expression of both genes (HR, 0.2; 95% CI, 0.1-0.5) compared with any other co-expression status of both genes, particularly for patients with surgery only (HR, 0.1; 95% CI, 0.0-0.9). CONCLUSION: These results suggest that altered expression of MMP11 and P14(ARF) in tumors may individually, or in combination, predict poor prognosis of LSCC, particularly for patients with surgery only.
Authors: Oneida A Arosarena; Eric W Barr; Ryan Thorpe; Hilary Yankey; Joseph T Tarr; Fayez F Safadi Journal: J Cell Physiol Date: 2017-04-25 Impact factor: 6.384
Authors: Wioletta Wujcicka; Agnieszka Zajac; Krzysztof Szyllo; Beata Smolarz; Hanna Romanowicz; Grzegorz Stachowiak Journal: In Vivo Date: 2020 Mar-Apr Impact factor: 2.155